Lupin shares continue to rise, trading at a new 52-week high of Rs 2,376 after a 15% return over two weeks. The Nifty Pharma ...

The stock of the pharmaceutical company, Lupin is quoting higher for the sixth straight trading day; it has rallied 10 per ...

Lupin Ltd. acquires Huminsulin range from Eli Lilly, strengthening its position in the Indian diabetes market.

Lupin strengthens its diabetes portfolio with the acquisition of Huminsulin products from Eli Lilly, including Insulin Human ...

There is a significant Indian population affected with diabetes for both Type 1 and Type 2 Diabetes Mellitus, where Insulin ...

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and ...

Nilesh Gupta, Managing Director of Lupin, emphasised that this acquisition aligns with the company’s commitment to expanding ...

Lupin Ltd has acquired the anti-diabetic medicine Huminsulin in India from Eli Lilly to expand its diabetes portfolio. This ...

Huminsulin is used for adult and pediatric patient with Type 1 and Type 2 diabetes mellitus that aids in regulation of blood ...

Lupin acquires Huminsulin from Eli Lilly to strengthen diabetes portfolio in India, offering affordable healthcare options.

Global pharma company Lupin announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly), aiming to ...

Lupin has acquired 'Huminsulin' in India from Eli Lilly and Company to strengthen its diabetes portfolio. The acquisition ...